Whistleblower backlog may start clearing

Lawmakers and not-for-profit groups are pushing the feds to help clear a backlog of some 900 whistleblower lawsuits--and a sizable number of those were filed against drugmakers, the Washington Post reports.

You know the type: Consider the Merck case, which the drugmaker paid $650 to settle; it alleged that the company failed to repay Medicaid rebates. Then there was the $515 million Bristol-Myers Squibb deal, which settled claims of illegal marketing and pricing. Sen. Charles Grassley (R-IA) is among those calling for the Department of Justice to make these investigations a priority. Whether that means we'll see more pharma settlements--well, we'll just have to wait and see.

- read the WP story

Suggested Articles

Saturday, AstraZeneca revealed more of the data that convinced the FDA to green-light Calquence in previously untreated chronic lymphocytic leukemia.

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.